Post

Conversation

The Economist on how China has sped up clinical trials and seen its biotech sector rise. China’s government identified biotech as a strategic priority nearly two decades ago. But it was not until 2015 that things really took off, after the national drug regulator launched ambitious reforms. It took on more staff and cleared a backlog of 20,000 drug applications in just two years. Clinical trials were streamlined and brought into step with global standards. A study by Yimin Cui of Peking University and colleagues, published in Nature Reviews Drug Discovery, found that the time taken to approve the first round of human trials fell to 87 days, from 501 days before the reforms. We also need this.
David Watson 🥑
Post your reply

There’s also a serious argument that US biotech investment is going into the wrong things from a national security perspective — too many bespoke skin creams, too few novel armor materials and anti-corrosion coatings:
Speeding up trials, increases the likelihood of shoddy testing and lab work. Let’s say a lab in Wuhan has a leak, in pursuit of bringing drugs to market at breakneck rates, what are the potential benefits and consequences for adopting this protocol.